KOP Therapeutics
NEWS & UPDATES

Latest from
KOP Therapeutics

Stay up to date with KOP Therapeutics' scientific milestones, partnership announcements, and corporate developments.

SCIENTIFIC MILESTONEJune 15, 2026FEATURED

Next-Generation Sequences Achieve Up to 95% Oncogene Knockdown in Preclinical Studies

KOP Therapeutics announces that next-generation ASO sequences have achieved up to 95% knockdown of target oncogenes in preclinical models — a substantial improvement over prior KOP-101 results, advancing the company's lead optimization program.

IN VIVO DATAMarch 10, 2026FEATURED

Charles River PC3 Xenograft Study Confirms Statistically Significant Tumor Growth Inhibition

KOP Therapeutics reports biostatistician-confirmed results from its KOP-101 PC3 xenograft study conducted at Charles River Laboratories. The study demonstrated statistically significant tumor growth inhibition (p=0.049), with 12.7% tumor reduction in treated animals versus 6.7% growth in controls.

PARTNERSHIPNovember 20, 2025FEATURED

KOP Therapeutics Engages Galenvs Sciences as Preferred CRO for Next-Stage Studies

KOP Therapeutics has selected Galenvs Sciences (Montreal, QC) as its preferred contract research organization for the upcoming 96-hour cancer cell kill study, which will determine ED50 and ED90 values for lead constructs.

PLATFORMAugust 5, 2025FEATURED

KOP Completes 95-Construct ASO Screen — Two Lead Candidates Identified

KOP Therapeutics has completed a systematic screen of 95 ASO constructs across three cancer cell lines. CCND1-016 (93% knockdown) and CCND1-015 (91% knockdown) were identified as lead candidates, with two additional mid-tier candidates showing reproducible activity.

SCIENTIFIC MILESTONE

June 15, 2026

Next-Generation Sequences Achieve Up to 95% Oncogene Knockdown in Preclinical Studies

KOP Therapeutics announces that next-generation ASO sequences have achieved up to 95% knockdown of target oncogenes in preclinical models — a substantial improvement over prior KOP-101 results, advancing the company's lead optimization program.

IN VIVO DATA

March 10, 2026

Charles River PC3 Xenograft Study Confirms Statistically Significant Tumor Growth Inhibition

KOP Therapeutics reports biostatistician-confirmed results from its KOP-101 PC3 xenograft study conducted at Charles River Laboratories. The study demonstrated statistically significant tumor growth inhibition (p=0.049), with 12.7% tumor reduction in treated animals versus 6.7% growth in controls.

PARTNERSHIP

November 20, 2025

KOP Therapeutics Engages Galenvs Sciences as Preferred CRO for Next-Stage Studies

KOP Therapeutics has selected Galenvs Sciences (Montreal, QC) as its preferred contract research organization for the upcoming 96-hour cancer cell kill study, which will determine ED50 and ED90 values for lead constructs.

PLATFORM

August 5, 2025

KOP Completes 95-Construct ASO Screen — Two Lead Candidates Identified

KOP Therapeutics has completed a systematic screen of 95 ASO constructs across three cancer cell lines. CCND1-016 (93% knockdown) and CCND1-015 (91% knockdown) were identified as lead candidates, with two additional mid-tier candidates showing reproducible activity.

Stay Informed

Sign up to receive KOP Therapeutics updates, scientific milestones, and investor news directly to your inbox.

CONTACT US VIEW PIPELINE
KOP Therapeutics

Advancing tumor-targeted RNA therapeutics toward IND-enabling development, partnership, and commercialization.

Preclinical Stage

DISCLAIMER

The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.

This communication contains forward-looking statements, which relate to future events or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.

COPYRIGHT AND TRADEMARK

The information in this presentation (including certain names, graphics, logos, icons, designs, words, titles or phrases) is protected by copyright and other laws and may not be copied, reproduced, modified, uploaded, posted, transmitted, or distributed in any way without KOP's prior written approval. Any unauthorized downloading, re-transmission, re-publication or other copying or modification of trademarks and/or the contents herein is strictly prohibited.

© 2026 KOP Therapeutics Inc. All rights reserved.

Montreal, Quebec, Canada · 604.256.9900